Development of treatment for papillary and anaplastic thyroid carcinoma by targeting cancer-specific aberrant protein

点击翻译按钮获取中文摘要

Suppression of BRAF expression in human anaplastic thyroid carcinoma cell line NPA, human papillary thyroid carcinoma cell line K1 those have BRAF mutation which is involved in malignant transformation and papillary thyroid carcinoma cell line TPC1 without BRAF mutation reduced expression of genes related to malignant transformation. In clinical thyroid carcinoma specimen, approximately 90% of cases have mutation in BRAF activating mutation. HSP90 inhibitor which is anticipated to reduce BRAF expression inhibits cell proliferation in other cancer cell lines.